Leveraging unique technology for creating novel microalgae strains from the environment, we provide microalgae strains useful for industrial and academic applications. Additionally, we offer; 1: consultation on microalgae business plans and experimental designs, 2: guidance on microalgae cultivation techniques, and 3: evaluation of microalgae strains based on growth rate and produced substances. We collaborate with diverse companies—spanning aquaculture, food, semiconductors, chemical materials, pet supplies, and rare metal recovery—as well as universities and research institutions to create new industries that address global challenges.
Solaris Bio revolutionizes regenerative medicine by integrating proprietary Animal-Origin-Free (AOF) formulation designs with advanced cell protection expertise. Centered on our "Organic Solvent-Free Cryopreservation Solution," which boasts the highest safety standards, we offer comprehensive cell manufacturing solutions, including world-class growth media. Leveraging innovative R&D and quality verified by the Certificate of Material Eligibility, we simultaneously enhance cell product efficacy and reduce costs, powerfully accelerating the social implementation of next-generation healthcare.
HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.
Our key product is Enteral Ventilation (EVA) technology, that supplies liquid oxygen to premature babies with serious respiratory problems through Gut-Mediated Oxygen Delivery. The program is at the clinical trial stage.
Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.
